Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asimadoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asimadoline SCHEMBL8011656 | 1.00 | OPRK1 (0.98) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL26923202 | 1.00 | OPRK1 (0.98) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL7721982 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL6923822 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL8717354 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL155020 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL13639176 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL2473545 | 0.99 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8720266 | 0.93 | OPRK1 (0.89) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9015325 | 0.93 | OPRK1 (0.89) | OPRK1OPRM1OPRD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877800-B2 | Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome | TIOGA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | claimed |
| EP-2636407-A2 | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | Tioga Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| EP-2561870-A1 | Kappa-Opiate Agonists For The Treatment Of Diarrhea-Predominant and Alternating Irritable Bowel Syndrome | Tioga Pharmaceuticals, Inc. (US) | 2013-02-27 | — | — | EP | claimed |
| EP-2136801-B1 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT AND ALTERNATING IRRITABLE BOWEL SYNDROME | TIOGA PHARMACEUTICALS INC (US) | 2012-08-29 | — | — | EP | claimed |
| CN-102641265-A | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-08-22 | — | — | CN | claimed |
| CN-101677997-B | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-05-09 | — | — | CN | claimed |
| US-7960429-B2 | especially N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide (Asimadoline) or salt; reduces symptoms of abnormal stool frequency, abnormal stool form, defecation straining, urgency, a feeling of incomplete bowel movement, passing mucus, and bloating | Tioga Pharmaceuticals, Inc (US) | 2011-06-14 | — | — | US | claimed |
| US-20110046174-A1 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME | TIOGA PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | claimed |
| CN-101677997-A | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | claimed |
| EP-2074997-A1 | Use of Asimadoline for the treatment of digestive disorders | Tioga Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20070179098-A1 | Treatment of functional dyspepsia using asimadoline | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-08-02 | — | — | US | claimed |
| US-20010051181-A1 | NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF ASIMADOLINE | VAN OSDOL WILLIAM W (US) | 2001-12-13 | — | — | US | claimed |
| EP-0761650-B1 | Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation | MERCK PATENT GMBH (DE) | 2001-10-31 | — | — | EP | claimed |
| US-6060504-A | N-methyl-N-[(1S)-1-phenyl-2-(3S)-hydroxypyrrolidin-1-yl)ethyl]-2-2-diphenylacetamide | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-05-09 | — | — | US | claimed |
| US-5977161-A | Administering asimadoline hydrochloride | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-11-02 | — | — | US | claimed |
| WO-1999032096-A1 | NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF ASIMADOLINE | ALZA CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| US-5776972-A | USE OF ASIMADOLINE HYDROCHLORIDE (N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydRoxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide hydrochloride) | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-07-07 | — | — | US | claimed |
| CN-1145781-A | Kappa-opiate agonists for inflammatory bowel disorders | MERCK PATENT GMBH (DE) | 1997-03-26 | — | — | CN | claimed |
| EP-0761650-A1 | Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation | MERCK PATENT GmbH (DE) | 1997-03-12 | — | — | EP | claimed |
| EP-0752246-A2 | Kappa opiate agonists for inflammatory gut diseases | MERCK PATENT GmbH (DE) | 1997-01-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046174-A1 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME | OPRD1, OPRK1, OPRL1 | OPRK1 2/4885OPRM1 4/4885OPRD1 1/4885 |
| US-20070179098-A1 | Treatment of functional dyspepsia using asimadoline | AADAC, CYP2A7, UGT2B7 | OPRK1 252/4885OPRM1 82/4885OPRD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.